LENZ Therapeutics (LENZ) Total Non-Current Liabilities (2020 - 2024)

LENZ Therapeutics (LENZ) has 5 years of Total Non-Current Liabilities data on file, last reported at $11.2 million in Q4 2024.

• Quarterly Total Non-Current Liabilities fell 40.4% year-over-year to $11.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $11.2 million (down 40.4% YoY) and the FY2024 annual result came in at $11.2 million, down 40.4% from the prior year.
• Total Non-Current Liabilities climbed to $11.2 million in Q4 2024 per LENZ's latest filing, from $8.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $62.9 million in Q2 2023 and bottomed at $7.9 million in Q2 2021.
• The 5-year median for Total Non-Current Liabilities is $17.0 million (2021), against an average of $23.6 million.
• The widest annual swing landed in 2023, when Total Non-Current Liabilities soared 289.41%; it then tumbled 85.97% in 2024.
• Tracing LENZ's Total Non-Current Liabilities over 5 years: stood at $32.0 million in 2020, then slumped by 44.03% to $17.9 million in 2021, then declined by 17.53% to $14.8 million in 2022, then increased by 27.28% to $18.8 million in 2023, then plunged by 40.4% to $11.2 million in 2024.
• Per Business Quant, the three latest LENZ Total Non-Current Liabilities figures stand at $11.2 million (Q4 2024), $8.7 million (Q3 2024), and $9.7 million (Q2 2024).

Peer Comparison